Knowledge HQ

The authors developed a GMP-feasible protocol for expanding TILs from sarcoma without anti-CD137 agonist, using CD3/CD28 beads instead. The rapid expansion phase (REP) utilized G-Rex® 10M, which achieved a 2- to 3-fold higher expansion compared to T-75 flasks, boosting clinical feasibility.

This study demonstrates a semi-automated workflow for non-viral CAR T-cell production using digitally connected instruments. T cells were isolated, activated, and then cultured in G-Rex® 100 and G-Rex® 100M. The process yielded high-quality CAR T cells with reduced manual touchpoints and variability.

This paper describes the engineering of allogeneic CD19 CAR T cells with FKBP12 knockout to resist mTOR inhibitors like tacrolimus and rapamycin. The study utilized 24-well G-Rex® plates for the recovery and expansion of nucleofected T cells. These cells demonstrated deep B-cell depletion in immunosuppressed mice.

This study presents a GMP-compliant process for manufacturing off-the-shelf NK cells from CD34+ HSPCs. The protocol was adapted to G-Rex® 10M and 100M to facilitate scaling and reduce handling. The resulting NK cells showed high recovery, viability, and potent anti-tumor activity in vivo and in vitro.

This poster explores using cryopreserved G-CSF-mobilized apheresis units for manufacturing CIK and CAR-CIK cells. It compares manual versus automated washing and expansion methods. The use of G-Rex® allowed for higher cell expansion in significantly less time (9-12 days) compared to standard.

This review addresses challenges in scaling iPSC-derived therapies, emphasizing automation, closed systems, and Quality-by-Design. It evaluates various technologies for expansion and differentiation. 1L and 5L G-Rex® are referenced as technologies used for expansion during research and early process development.

This study establishes a GMP-compliant protocol for expanding thymus-derived regulatory T cells (Thy-Tregs). By optimizing CD8 depletion, CD25 enrichment, and cytokine stimulation, the authors achieved high purity. G-Rex® (G-Rex® 10 and 100) were successfully used to scale up production for clinical trials.

This study analyzes adaptive immune responses in PSC. Cells were pulsed with peptides in a 24-well G-Rex® device to generate EBV-specific T cell lines.

RAPA-201 T cells, reprogrammed via mTOR inhibition, showed safety and efficacy in RRMM patients. The manufacturing process involved incubating cells in G-Rex® culture vessels with cytokines and rapamycin.

The authors demonstrate that DNA-PK inhibitors enhance CRISPR/Cas9 KI efficiency. Under GMP-optimized conditions, T cells were cultured in G-Rex®-100M vessels and seeded in G-Rex® 24 well plates after electroporation.

The study evaluates Pin-EGFR-armed eNK cells. CD3-negative cells were seeded into G-Rex® 6M devices for expansion and transferred to 100 M G-Rex® on day 7.

The NEO-STIM process generates high-frequency T cell responses to KRAS neoantigens. The protocol utilizes G-Rex® 24 Well Plates, G-Rex® 6 Well Plates, and G-Rex® 100M/500M closed-system vessels for cell culture and expansion.